Fractyl Health GUTS
- Market cap
- $14.3M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Fractyl Health's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $36K | $7K | $33K+560% | $43K−40% | $14K−61% | $3K−57% | n/a | n/a | n/a | n/a | n/a | n/a | |
| Cost of revenue | $25K | $2K | $19K+533% | $24K−49% | $7K−72% | $0 | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | $11K | $5K | $14K+600% | $19K−24% | $7K−36% | $3K−40% | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $9.4M | $10.2M | $14.4M+54% | $16.8M+83% | $19M+103% | $20.3M+100% | $19.4M+35% | $21.2M+26% | $17.5M−8% | $16.5M−19% | $15.6M−20% | $13.8M−35% |
| SG&A | $4.5M | $2.8M | $7.1M+158% | $6.2M+126% | $4.8M+7% | $4.9M+75% | $5.3M−25% | $4.9M−21% | $5.2M+9% | $6.8M+38% | $5.2M−2% | $5.3M+7% |
| −$13.9M | −$13M | −$21.5M+78% | −$23M+94% | −$23.8M+72% | −$25.2M+94% | −$24.8M+15% | −$26.1M+14% | −$22.7M−5% | −$23.3M−8% | −$20.8M−16% | −$19.1M−27% | |
| Net income | −$15.7M | −$19.2M | −$3.3M−72% | −$17.2M−43% | −$23.2M+47% | −$25M+30% | −$23.7M+615% | −$27.9M+62% | −$45.6M+97% | −$43.7M+75% | $9.2M | −$25.5M−8% |
| −$115.32 | −$134.16 | −$2.04−98% | −$4.32−98% | −$5.76−95% | −$6.24−95% | −$5.88+188% | −$6.84+58% | −$8.52+48% | −$3.72−40% | $0.72 | −$1.92−72% | |
| 174.2K | 175.2K | 2.5M+1347% | 4M+2206% | 4M+2196% | 4M+2205% | 4.1M+64% | 4.1M+2% | 5.4M+35% | 11.7M+189% | 13.2M+224% | 13.2M+224% |
EPS, diluted: 3 periods, Q4 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Fractyl Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GUTSFractyl Health | $14.3M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% |
Investors who own it
Investors we follow who held Fractyl Health at the end of Jun 30, 2026, from their 13F filings.
- Lee AinslieMaverick Capital0.0% of portfolio
More on Fractyl Health
Each number over time
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .